A Phase 3 Study of Bardoxolone Methyl in Patients With Diabetic Kidney Disease; AYAME Study

NCT03550443 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

1323

Enrollment

INDUSTRY

Sponsor class

Stopped Based on results of double-blind parts, it was determined that it would be difficult to submit a marketing authorization application for RTA 402 for diabetic kidney disease.

Conditions

Diabetic Kidney Disease

Interventions

DRUG: Bardoxolone methyl
DRUG: Placebo

Sponsor

Kyowa Kirin Co., Ltd.